September 4, 2020
This article was originally published by The Limbic The anti-CD38 mAb daratumumab (Darzalex) has received a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) for PBS listing as a second line treatment in combination with bortezomib and dexamethasone for patients with multiple myeloma. The drug was recommended on the basis that it should be available...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand